Molecular Partners AG SEC filings MOLN
Molecular Partners AG has 121 filings in SEC EDGAR's recent list, going back to Mar 15, 2021. Its latest annual report, Form 20-F, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 25, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 20, 2026 | Jul 16, 2026 |
| 6-K | Current report (foreign issuer) | Jul 7, 2026 | Jul 6, 2026 |
| 6-K | Current report (foreign issuer) | Jul 2, 2026 | Jul 2, 2026 |
| 6-K | Current report (foreign issuer) | Jun 1, 2026 | May 30, 2026 |
| 6-K | Current report (foreign issuer) | May 12, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | May 1, 2026 | May 1, 2026 |
| 6-K | Current report (foreign issuer) | Apr 14, 2026 | Apr 14, 2026 |
| 6-K | Current report (foreign issuer) | Mar 30, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | Mar 13, 2026 | Mar 12, 2026 |
| 6-K | Current report (foreign issuer) | Mar 12, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Feb 2, 2026 | Feb 2, 2026 |
| 6-K | Current report (foreign issuer) | Jan 12, 2026 | Jan 11, 2026 |
| 6-K | Current report (foreign issuer) | Dec 8, 2025 | Dec 7, 2025 |
| 6-K | Current report (foreign issuer) | Nov 12, 2025 | Nov 12, 2025 |
| 6-K | Current report (foreign issuer) | Oct 30, 2025 | Sep 30, 2025 |
| 6-K | Current report (foreign issuer) | Aug 25, 2025 | Jun 30, 2025 |
| 6-K | Current report (foreign issuer) | Jun 12, 2025 | Jun 12, 2025 |
| 6-K | Current report (foreign issuer) | May 15, 2025 | Mar 31, 2025 |
| 6-K | Current report (foreign issuer) | Apr 29, 2025 | Apr 29, 2025 |
| 6-K | Current report (foreign issuer) | Mar 6, 2025 | Mar 6, 2025 |
| 6-K | Current report (foreign issuer) | Mar 6, 2025 | Dec 31, 2024 |
| 6-K | Current report (foreign issuer) | Jan 13, 2025 | Jan 12, 2025 |
| 6-K | Current report (foreign issuer) | Jan 13, 2025 | Jan 12, 2025 |
| 6-K | Current report (foreign issuer) | Oct 31, 2024 | Sep 30, 2024 |
| 6-K | Current report (foreign issuer) | Oct 28, 2024 | Oct 28, 2024 |
| 6-K | Current report (foreign issuer) | Oct 22, 2024 | Oct 22, 2024 |
| 6-K | Current report (foreign issuer) | Aug 26, 2024 | Jun 30, 2024 |
| 6-K | Current report (foreign issuer) | Jun 14, 2024 | Jun 14, 2024 |
| 6-K | Current report (foreign issuer) | Jun 11, 2024 | Jun 11, 2024 |
| 6-K | Current report (foreign issuer) | Jun 3, 2024 | Jun 1, 2024 |
| 6-K/A | Filing | May 17, 2024 | Mar 31, 2024 |
| 6-K | Current report (foreign issuer) | May 16, 2024 | Mar 31, 2024 |
| 6-K | Current report (foreign issuer) | Mar 26, 2024 | Mar 26, 2024 |
| 6-K | Current report (foreign issuer) | Jan 8, 2024 | Jan 7, 2024 |
| 6-K | Current report (foreign issuer) | Jan 5, 2024 | Jan 5, 2024 |
| 6-K | Current report (foreign issuer) | Dec 11, 2023 | Dec 10, 2023 |
| 6-K | Current report (foreign issuer) | Nov 2, 2023 | Nov 2, 2023 |
| 6-K | Current report (foreign issuer) | Oct 26, 2023 | Sep 30, 2023 |
| 6-K | Current report (foreign issuer) | Aug 24, 2023 | Jun 30, 2023 |
| 6-K | Current report (foreign issuer) | May 12, 2023 | May 12, 2023 |
| 6-K | Current report (foreign issuer) | May 11, 2023 | May 11, 2023 |
| 6-K | Current report (foreign issuer) | Mar 13, 2023 | Mar 13, 2023 |
| 6-K | Current report (foreign issuer) | Mar 9, 2023 | Mar 9, 2023 |
| 6-K | Current report (foreign issuer) | Jan 17, 2023 | Jan 16, 2023 |
| 6-K | Current report (foreign issuer) | Nov 10, 2022 | Nov 10, 2022 |
| 6-K | Current report (foreign issuer) | Oct 27, 2022 | Oct 27, 2022 |
| 6-K | Current report (foreign issuer) | Oct 27, 2022 | Sep 30, 2022 |
| 6-K/A | Filing | Aug 31, 2022 | Jun 30, 2022 |
| 6-K | Current report (foreign issuer) | Aug 25, 2022 | Aug 25, 2022 |
| 6-K | Current report (foreign issuer) | Jun 13, 2022 | Jun 13, 2022 |
| 6-K | Current report (foreign issuer) | May 12, 2022 | May 12, 2022 |
| 6-K | Current report (foreign issuer) | Apr 26, 2022 | Apr 26, 2022 |
| 6-K | Current report (foreign issuer) | Apr 26, 2022 | Apr 26, 2022 |
| 6-K | Current report (foreign issuer) | Apr 14, 2022 | Apr 13, 2022 |
| 6-K | Current report (foreign issuer) | Mar 17, 2022 | Mar 17, 2022 |
| 6-K | Current report (foreign issuer) | Mar 15, 2022 | Mar 15, 2022 |
| 6-K | Current report (foreign issuer) | Feb 10, 2022 | Feb 10, 2022 |
| 6-K | Current report (foreign issuer) | Jan 18, 2022 | Jan 18, 2022 |
| 6-K | Current report (foreign issuer) | Jan 10, 2022 | Jan 10, 2022 |
| 6-K | Current report (foreign issuer) | Dec 15, 2021 | Dec 15, 2021 |
| 6-K | Current report (foreign issuer) | Dec 14, 2021 | Dec 14, 2021 |
| 6-K | Current report (foreign issuer) | Dec 13, 2021 | Dec 12, 2021 |
| 6-K | Current report (foreign issuer) | Nov 30, 2021 | Nov 30, 2021 |
| 6-K | Current report (foreign issuer) | Nov 16, 2021 | Nov 16, 2021 |
| 6-K | Current report (foreign issuer) | Oct 28, 2021 | Oct 28, 2021 |
| 6-K | Current report (foreign issuer) | Aug 26, 2021 | Aug 26, 2021 |
| 6-K | Current report (foreign issuer) | Aug 9, 2021 | Aug 9, 2021 |
| 6-K | Current report (foreign issuer) | Jul 8, 2021 | Jul 8, 2021 |
Showing 70 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MOLN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Schlieren-Zurich, Switzerland
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1745114
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.